Toxicity of two cisplatin‐based radiochemotherapy regimens for the treatment of patients with stage III/IV head and neck cancer

Abstract

Two courses of fractionated cisplatin (20 mg/m(2)/d) and 5-FU were associated with significantly less acute toxicity than were 3 courses cisplatin (100 mg/m(2)/d).